Featured Publications
Antiplatelet regimens following carotid artery revascularization
Lee M, Ahmed ZV, Huang J, Brice A, Arham A, Castro-Dominguez Y, Aboian E, Nagpal S, Smolderen KG, Mena-Hurtado C. Antiplatelet regimens following carotid artery revascularization. American Heart Journal 2022, 253: 48-52. PMID: 35863439, DOI: 10.1016/j.ahj.2022.07.004.Peer-Reviewed Original ResearchMeSH KeywordsCarotid ArteriesCarotid StenosisEndarterectomy, CarotidHumansPlatelet Aggregation InhibitorsRetrospective StudiesRisk FactorsStentsStrokeTreatment OutcomeConceptsDual antiplatelet therapySingle antiplatelet therapyCarotid artery stentingCarotid endarterectomyAntiplatelet therapyReal-world clinical practiceCarotid artery revascularizationLow adherence ratesArtery revascularizationArtery stentingAdherence ratesClinical practicePatientsTherapyEngland dataHigh percentageRevascularizationAntiplateletEndarterectomyStenting
2024
Antithrombotic Strategies for Patients With Peripheral Artery Disease JACC Scientific Statement
Bonaca M, Barnes G, Bauersachs R, Bessada Y, Conte M, Dua A, Hess C, Serhal M, Mena-Hurtado C, Weitz J, Beckman J. Antithrombotic Strategies for Patients With Peripheral Artery Disease JACC Scientific Statement. Journal Of The American College Of Cardiology 2024, 84: 936-952. PMID: 39197984, DOI: 10.1016/j.jacc.2024.06.027.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsFibrinolytic AgentsHumansPeripheral Arterial DiseasePlatelet Aggregation InhibitorsConceptsPeripheral arterial diseaseAntithrombotic strategiesArtery diseaseResponse to antithrombotic therapyLimb eventsRisk of bleedingCoronary artery diseaseAdverse limb eventsAntithrombotic therapyMultidisciplinary working groupClinical scenariosPatientsAssessment of benefit-riskBenefit-riskAnticoagulationDiseaseScientific statementPatient-centeredBleeding
2022
Variability in Antithrombotic Therapy after Infrainguinal Lower Extremity Bypass
Brahmandam A, Lee M, Bellamkonda K, Provance JB, Sumpio B, Ochoa Chaar CI, Smolderen KG, Mena-Hurtado C, Guzman RJ. Variability in Antithrombotic Therapy after Infrainguinal Lower Extremity Bypass. Annals Of Vascular Surgery 2022, 88: 51-62. PMID: 36245106, DOI: 10.1016/j.avsg.2022.08.016.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsFibrinolytic AgentsHumansIschemiaLower ExtremityPeripheral Arterial DiseasePlatelet Aggregation InhibitorsRetrospective StudiesRisk FactorsTreatment OutcomeConceptsInfrainguinal lower extremity bypassLower extremity bypassDual antiplatelet therapySingle antiplatelet therapyAntithrombotic therapyCombination therapyAntiplatelet therapyMedian odds ratioExtremity bypassDistal targetsHierarchical multivariable logistic regressionCenter-level variabilityCommon combination therapyPatient-level factorsPercutaneous coronary interventionPeripheral vascular interventionsMultivariable logistic regressionMultivariable regression modelsAntiplatelet monotherapyBypass targetAntithrombotic regimensPostoperative bleedingTriple therapyCoronary interventionAntithrombotic strategies
2021
Real-world antithrombotic treatment variability in patients undergoing peripheral vascular intervention: Insights from the VQI registry
Lee M, Ahmed ZV, Huang J, Jelani QU, Aboian E, Peri-Okonny PA, Smolderen KG, Mena-Hurtado C. Real-world antithrombotic treatment variability in patients undergoing peripheral vascular intervention: Insights from the VQI registry. American Heart Journal 2021, 244: 31-35. PMID: 34688650, DOI: 10.1016/j.ahj.2021.10.186.Peer-Reviewed Original ResearchMeSH KeywordsDual Anti-Platelet TherapyFibrinolytic AgentsHumansPlatelet Aggregation InhibitorsRegistriesRisk FactorsTreatment OutcomeConceptsPeripheral vascular interventionsDual antiplatelet therapySingle antiplatelet therapyAntiplatelet therapyVascular interventionsOptimal medical therapyNew trial dataAntithrombotic prescriptionMedical therapyPrescription ratesProvider factorsVQI registryTrial dataTherapyHealth systemPatientsTreatment variabilityPractice levelInterventionHigh levelsRegistryPhysiciansLack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia
Llanos-Chea F, Jelani QU, Trejo-Paredes C, Curtis JP, Parzynski CS, Huang J, Faridi KF, Turner J, Smolderen KG, Mena-Hurtado C. Lack of Guideline-Directed Medical Therapy in Patients Undergoing Endovascular Procedures for Critical Limb Ischemia. Journal Of The American College Of Cardiology 2021, 77: 1374-1375. PMID: 33706882, DOI: 10.1016/j.jacc.2020.12.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCohort StudiesEndovascular ProceduresFemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIschemiaMaleMiddle AgedPeripheral Arterial DiseasePlatelet Aggregation Inhibitors
2020
Physical Activity After Treatment for Symptomatic Peripheral Artery Disease
Peri-Okonny PA, Patel S, Spertus JA, Jackson EA, Malik AO, Provance J, Mena-Hurtado C, Shishehbor MH, Hijjaji V, Gosch KL, Smolderen K. Physical Activity After Treatment for Symptomatic Peripheral Artery Disease. The American Journal Of Cardiology 2020, 138: 107-113. PMID: 33065083, PMCID: PMC7736254, DOI: 10.1016/j.amjcard.2020.10.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnkle Brachial IndexConservative TreatmentEndovascular ProceduresExerciseExercise TherapyFemaleHealth StatusHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIntermittent ClaudicationLeisure ActivitiesLinear ModelsLogistic ModelsMaleMiddle AgedMultivariate AnalysisPatient SatisfactionPeripheral Arterial DiseasePlatelet Aggregation InhibitorsQuality of LifeSedentary BehaviorSmoking CessationSocial InteractionVascular Surgical ProceduresWorkConceptsPhysical activity levelsPhysical activityInvasive treatmentSymptomatic peripheral artery diseasePeripheral artery diseaseMultivariable logistic regressionAssociation of treatmentActivity levelsMultivariable linear regressionHealth status changesHealth status gainsPAD outcomesArtery diseaseVascular clinicInvasive groupNoninvasive treatmentHealth statusLogistic regressionActivity statusLTPAClaudicationTreatmentPatientsStatus changesAssociation
2019
Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion
Attaran RR, Ozdemir D, Lin IH, Mena-Hurtado C, Lansky A. Evaluation of anticoagulant and antiplatelet therapy after iliocaval stenting: Factors associated with stent occlusion. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2019, 7: 527-534. PMID: 31203859, DOI: 10.1016/j.jvsv.2019.01.058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsEndovascular ProceduresFemaleHumansIliac VeinMaleMay-Thurner SyndromeMiddle AgedPlatelet Aggregation InhibitorsPostthrombotic SyndromeProsthesis DesignRecurrenceRetrospective StudiesStentsTime FactorsTreatment OutcomeVascular PatencyVena Cava, InferiorVenous ThrombosisConceptsAcute deep vein thrombosisPost-thrombotic syndromeDeep vein thrombosisMay-Thurner syndromeDuration of anticoagulationAntiplatelet therapyPatency ratesIliocaval stentingIpsilateral deep vein thrombosisIliocaval venous stentingPrimary patency rateStent patency ratesCommon femoral veinVariety of indicationsLarge teaching hospitalVein thrombosisVenous stentingRetrospective reviewDVT groupStent groupFemoral veinProcedural dataStent patencyStent occlusionTeaching hospital
2016
Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011)
Arora S, Panaich SS, Patel N, Patel NJ, Lahewala S, Thakkar B, Savani C, Jhamnani S, Singh V, Patel N, Patel S, Sonani R, Patel A, Tripathi B, Deshmukh A, Chothani A, Patel J, Bhatt P, Mohamad T, Remetz MS, Curtis JP, Attaran RR, Mena CI, Schreiber T, Grines C, Cleman M, Forrest JK, Badheka AO. Impact of Glycoprotein IIb/IIIa Inhibitors Use on Outcomes After Lower Extremity Endovascular Interventions From Nationwide Inpatient Sample (2006–2011). Catheterization And Cardiovascular Interventions 2016, 88: 605-616. PMID: 26914274, DOI: 10.1002/ccd.26452.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAmputation, SurgicalCross-Sectional StudiesDatabases, FactualDrug CostsEndovascular ProceduresFemaleHospital CostsHospital MortalityHumansLimb SalvageLogistic ModelsLower ExtremityMaleMiddle AgedMultivariate AnalysisOdds RatioPeripheral Arterial DiseasePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPropensity ScoreRisk FactorsTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsGlycoprotein IIb/IIIa inhibitorsPeripheral endovascular interventionsHospital mortalityHospitalization costsEndovascular interventionGPI useAmputation rateUtilization Project Nationwide Inpatient Sample databaseTwo-level hierarchical multivariateIIb/IIIa inhibitorsNationwide Inpatient Sample databaseLower amputation ratesPaucity of dataHospital outcomesPostprocedural complicationsSecondary outcomesPropensity matchingStudy cohortHealthcare costsICD-9Multivariate analysisStudy outcomesSample databaseMortalityHierarchical multivariate
2014
Management of Symptomatic Carotid Disease in 2014
Litsky J, Stilp E, Njoh R, Mena-Hurtado C. Management of Symptomatic Carotid Disease in 2014. Current Cardiology Reports 2014, 16: 462. PMID: 24464307, DOI: 10.1007/s11886-013-0462-3.Peer-Reviewed Original ResearchMeSH KeywordsAngioplastyAntihypertensive AgentsCarotid StenosisEndarterectomy, CarotidHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPlatelet Aggregation InhibitorsStentsStrokeTime FactorsConceptsSymptomatic carotid stenosisCarotid artery stentingCarotid endarterectomyCarotid stenosisMedical therapyHigh-grade symptomatic carotid stenosisExtracranial carotid artery stenosisPreventive medical therapyClass I recommendationSymptomatic carotid diseaseCarotid artery stenosisCause of deathRetinal symptomsStroke preventionArtery stentingI recommendationLandmark trialsPerioperative eventsArtery stenosisCarotid diseaseSymptomatic lesionsNoninvasive evaluationStenosisTherapyModern management